Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 1244 · Reducing Drug Prices for Seniors Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–102 Prescription drug benefits

+8 −1Shown
More for 42 U.S.C. § 1395w–102
Read § 1395w–102Only this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in paragraph (2)(A), in the matter preceding clause (i), by striking and (9) and inserting , (9), and (10); and

  2. Carried out:

    by adding at the end the following new paragraph:(10) Requirement that coinsurance for covered part D drugs be based on the actual acquisition cost of the drug.— (A) In general.— For plan years beginning on or after January 1, 2026, for costs above the annual deductible specified in paragraph (1) and below the annual …

  3. Carried out:

    in subsection (c), by adding at the end the following new paragraph:(7) Requirement that coinsurance for covered part D drugs be based on the net price of the drug.— The coverage is provided in accordance with subsection (b)(10)..

§ 1395w–102(b)Standard prescription drug coverage(1)–(2)

Start of § 1395w–102 to (b)(1)(A)(ii) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(B)(B) Rounding(B) Rounding
Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.
(2)(2) Benefit structure(2) Benefit structure
(2)(A)(A) 25 percent coinsurance(A) 25 percent coinsurance
Subject to subparagraphs (C), (D), and (E) and paragraphs (8) [struck: and] (9), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—Subject to subparagraphs (C), (D), and (E) and paragraphs (8) [inserted: ,] (9), [inserted: and (10), ]the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—
(2)(A)(i)(i) (i)
equal to 25 percent; orequal to 25 percent; or
(2)(A)(ii)(ii) (ii)
actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.

§ 1395w–102(b)–(c)

(b)(2)(B)–(9)(D) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(b)(9)(D)(ii)(III)(III) (III)
an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.
(b)(9)(E)(E) Special rule for first 3 months of 2023(E) Special rule for first 3 months of 2023
With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.
(b)(10)(10) [inserted: Requirement that coinsurance for covered part D drugs be based on the actual acquisition cost of the drug.—]
(b)(10)(A)(A) [inserted: In general.—]
[inserted: For plan years beginning on or after January 1, 2026, for costs above the annual deductible specified in paragraph (1) and below the annual out-of-pocket threshold specified in paragraph (4), any coinsurance amount for a covered part D drug (insofar as such covered part D drug is included on the formulary and subject to coinsurance rather than a copayment) shall be calculated based on the actual acquisition cost (and not the wholesale acquisition cost) of such covered part D drug if such actual acquisition cost is lower than the wholesale acquisition cost of such covered part D drug. The preceding sentence shall not apply to a covered part D drug described in paragraph (8) or (9).]
(b)(10)(B)(B) [inserted: Actual acquisition cost defined.—]
[inserted: In this paragraph, the term “actual acquisition cost” means, with respect to a covered part D drug, the negotiated price of the covered part D drug under the prescription drug plan or MA–PD plan, net of any manufacturer-provided price concessions (as defined under section 423.100 of title 42, Code of Federal Regulations (or any successor regulation)), as reported for such drug in the Detailed DIR Report (or any successor report) submitted by the sponsor or organization offering the plan for the previous plan year.]
(c)(c) Alternative prescription drug coverage requirements(c) Alternative prescription drug coverage requirements
A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:
(c)(1)(1) Assuring at least actuarially equivalent coverage(1) Assuring at least actuarially equivalent coverage

§ 1395w–102(c)–(d)

(c)(1)(A)–(4) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(5)(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices
The coverage is in accordance with subsection (b)(8).The coverage is in accordance with subsection (b)(8).
(c)(6)(6) Treatment of cost-sharing for covered insulin products(6) Treatment of cost-sharing for covered insulin products
The coverage is provided in accordance with subsection (b)(9).The coverage is provided in accordance with subsection (b)(9).
(c)(7)(7) [inserted: Requirement that coinsurance for covered part D drugs be based on the net price of the drug.—]
[inserted: The coverage is provided in accordance with subsection (b)(10).]
(d)(d) Access to negotiated prices(d) Access to negotiated prices
(d)(1)(1) Access(1) Access
(d)(1)(A)(A) In general(A) In general
Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).

Rest of § 1395w–102 unchanged

Step through the changes